AU2001287289A1 - Vasopeptidase inhibitors to treat isolated systolic hypertensions - Google Patents

Vasopeptidase inhibitors to treat isolated systolic hypertensions

Info

Publication number: AU2001287289A1
Authority: AU; Australia
Prior art keywords: group; oxo; inhibitor; vasopeptidase; vasopeptidase inhibitor
Prior art date: 2000-04-03
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.): Abandoned

Application number

AU2001287289A

Other languages

English (en)

Inventor

Paul I. Chang

Richard A. Reeves

Robert A. Wolf

Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)

Bristol Myers Squibb Co

Original Assignee

Bristol Myers Squibb Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-04-03

Filing date

2001-03-15

Publication date

2001-10-15

2001-03-15 Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co

2001-10-15 Publication of AU2001287289A1 publication Critical patent/AU2001287289A1/en

Status Abandoned legal-status Critical Current

Links

239000003112 inhibitor Substances 0.000 title claims description 34
206010042957 Systolic hypertension Diseases 0.000 title claims description 19
LVRLSYPNFFBYCZ-VGWMRTNUSA-N omapatrilat Chemical group C([C@H](S)C(=O)N[C@H]1CCS[C@H]2CCC[C@H](N2C1=O)C(=O)O)C1=CC=CC=C1 LVRLSYPNFFBYCZ-VGWMRTNUSA-N 0.000 claims description 22
229950000973 omapatrilat Drugs 0.000 claims description 22
150000003839 salts Chemical class 0.000 claims description 10
239000003795 chemical substances by application Substances 0.000 claims description 7
239000002934 diuretic Substances 0.000 claims description 6
-1 2- mercapto-l-oxo-3-phenylpropyl Chemical group 0.000 claims description 5
JZUFKLXOESDKRF-UHFFFAOYSA-N Chlorothiazide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC2=C1NCNS2(=O)=O JZUFKLXOESDKRF-UHFFFAOYSA-N 0.000 claims description 5
208000029078 coronary artery disease Diseases 0.000 claims description 5
229960002003 hydrochlorothiazide Drugs 0.000 claims description 5
229940030600 antihypertensive agent Drugs 0.000 claims description 4
239000002220 antihypertensive agent Substances 0.000 claims description 4
239000000203 mixture Substances 0.000 claims description 4
208000023516 stroke disease Diseases 0.000 claims description 4
229940121710 HMGCoA reductase inhibitor Drugs 0.000 claims description 3
239000002333 angiotensin II receptor antagonist Substances 0.000 claims description 3
229940127218 antiplatelet drug Drugs 0.000 claims description 3
239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 claims description 3
239000000106 platelet aggregation inhibitor Substances 0.000 claims description 3
OJRHUICOVVSGSY-RXMQYKEDSA-N (2s)-2-chloro-3-methylbutan-1-ol Chemical compound CC(C)[C@H](Cl)CO OJRHUICOVVSGSY-RXMQYKEDSA-N 0.000 claims description 2
ZGGHKIMDNBDHJB-NRFPMOEYSA-M (3R,5S)-fluvastatin sodium Chemical compound [Na+].C12=CC=CC=C2N(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 ZGGHKIMDNBDHJB-NRFPMOEYSA-M 0.000 claims description 2
METKIMKYRPQLGS-GFCCVEGCSA-N (R)-atenolol Chemical compound CC(C)NC[C@@H](O)COC1=CC=C(CC(N)=O)C=C1 METKIMKYRPQLGS-GFCCVEGCSA-N 0.000 claims description 2
WLRMANUAADYWEA-NWASOUNVSA-N (S)-timolol maleate Chemical compound OC(=O)\C=C/C(O)=O.CC(C)(C)NC[C@H](O)COC1=NSN=C1N1CCOCC1 WLRMANUAADYWEA-NWASOUNVSA-N 0.000 claims description 2
FEDJGPQLLNQAIY-UHFFFAOYSA-N 2-[(6-oxo-1h-pyridazin-3-yl)oxy]acetic acid Chemical compound OC(=O)COC=1C=CC(=O)NN=1 FEDJGPQLLNQAIY-UHFFFAOYSA-N 0.000 claims description 2
MEAPRSDUXBHXGD-UHFFFAOYSA-N 3-chloro-n-(4-propan-2-ylphenyl)propanamide Chemical compound CC(C)C1=CC=C(NC(=O)CCCl)C=C1 MEAPRSDUXBHXGD-UHFFFAOYSA-N 0.000 claims description 2
BSYNRYMUTXBXSQ-UHFFFAOYSA-N Aspirin Chemical compound CC(=O)OC1=CC=CC=C1C(O)=O BSYNRYMUTXBXSQ-UHFFFAOYSA-N 0.000 claims description 2
239000002083 C09CA01 - Losartan Substances 0.000 claims description 2
239000002080 C09CA02 - Eprosartan Substances 0.000 claims description 2
239000004072 C09CA03 - Valsartan Substances 0.000 claims description 2
239000002947 C09CA04 - Irbesartan Substances 0.000 claims description 2
PCZOHLXUXFIOCF-UHFFFAOYSA-N Monacolin X Natural products C12C(OC(=O)C(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 PCZOHLXUXFIOCF-UHFFFAOYSA-N 0.000 claims description 2
RYMZZMVNJRMUDD-UHFFFAOYSA-N SJ000286063 Natural products C12C(OC(=O)C(C)(C)CC)CC(C)C=C2C=CC(C)C1CCC1CC(O)CC(=O)O1 RYMZZMVNJRMUDD-UHFFFAOYSA-N 0.000 claims description 2
DOQPXTMNIUCOSY-UHFFFAOYSA-N [4-cyano-4-(3,4-dimethoxyphenyl)-5-methylhexyl]-[2-(3,4-dimethoxyphenyl)ethyl]-methylazanium;chloride Chemical compound [H+].[Cl-].C1=C(OC)C(OC)=CC=C1CCN(C)CCCC(C#N)(C(C)C)C1=CC=C(OC)C(OC)=C1 DOQPXTMNIUCOSY-UHFFFAOYSA-N 0.000 claims description 2
229960001138 acetylsalicylic acid Drugs 0.000 claims description 2
ZPBWCRDSRKPIDG-UHFFFAOYSA-N amlodipine benzenesulfonate Chemical group OS(=O)(=O)C1=CC=CC=C1.CCOC(=O)C1=C(COCCN)NC(C)=C(C(=O)OC)C1C1=CC=CC=C1Cl ZPBWCRDSRKPIDG-UHFFFAOYSA-N 0.000 claims description 2
229960004005 amlodipine besylate Drugs 0.000 claims description 2
229960002274 atenolol Drugs 0.000 claims description 2
229960001770 atorvastatin calcium Drugs 0.000 claims description 2
239000002876 beta blocker Substances 0.000 claims description 2
229940030611 beta-adrenergic blocking agent Drugs 0.000 claims description 2
230000003185 calcium uptake Effects 0.000 claims description 2
NPAKNKYSJIDKMW-UHFFFAOYSA-N carvedilol Chemical compound COC1=CC=CC=C1OCCNCC(O)COC1=CC=CC2=NC3=CC=C[CH]C3=C12 NPAKNKYSJIDKMW-UHFFFAOYSA-N 0.000 claims description 2
229960004195 carvedilol Drugs 0.000 claims description 2
229940052311 cerivastatin sodium Drugs 0.000 claims description 2
GPUADMRJQVPIAS-QCVDVZFFSA-M cerivastatin sodium Chemical compound [Na+].COCC1=C(C(C)C)N=C(C(C)C)C(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)=C1C1=CC=C(F)C=C1 GPUADMRJQVPIAS-QCVDVZFFSA-M 0.000 claims description 2
GKTWGGQPFAXNFI-HNNXBMFYSA-N clopidogrel Chemical group C1([C@H](N2CC=3C=CSC=3CC2)C(=O)OC)=CC=CC=C1Cl GKTWGGQPFAXNFI-HNNXBMFYSA-N 0.000 claims description 2
229960003958 clopidogrel bisulfate Drugs 0.000 claims description 2
229960005316 diltiazem hydrochloride Drugs 0.000 claims description 2
229940030606 diuretics Drugs 0.000 claims description 2
229960004563 eprosartan Drugs 0.000 claims description 2
OROAFUQRIXKEMV-LDADJPATSA-N eprosartan Chemical compound C=1C=C(C(O)=O)C=CC=1CN1C(CCCC)=NC=C1\C=C(C(O)=O)/CC1=CC=CS1 OROAFUQRIXKEMV-LDADJPATSA-N 0.000 claims description 2
229960000868 fluvastatin sodium Drugs 0.000 claims description 2
229960002198 irbesartan Drugs 0.000 claims description 2
YCPOHTHPUREGFM-UHFFFAOYSA-N irbesartan Chemical compound O=C1N(CC=2C=CC(=CC=2)C=2C(=CC=CC=2)C=2[N]N=NN=2)C(CCCC)=NC21CCCC2 YCPOHTHPUREGFM-UHFFFAOYSA-N 0.000 claims description 2
229960004773 losartan Drugs 0.000 claims description 2
KJJZZJSZUJXYEA-UHFFFAOYSA-N losartan Chemical compound CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C=2[N]N=NN=2)C=C1 KJJZZJSZUJXYEA-UHFFFAOYSA-N 0.000 claims description 2
229960004844 lovastatin Drugs 0.000 claims description 2
PCZOHLXUXFIOCF-BXMDZJJMSA-N lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 claims description 2
QLJODMDSTUBWDW-UHFFFAOYSA-N lovastatin hydroxy acid Natural products C1=CC(C)C(CCC(O)CC(O)CC(O)=O)C2C(OC(=O)C(C)CC)CC(C)C=C21 QLJODMDSTUBWDW-UHFFFAOYSA-N 0.000 claims description 2
229960001300 metoprolol tartrate Drugs 0.000 claims description 2
229940096701 plain lipid modifying drug hmg coa reductase inhibitors Drugs 0.000 claims description 2
229960001495 pravastatin sodium Drugs 0.000 claims description 2
VWBQYTRBTXKKOG-IYNICTALSA-M pravastatin sodium Chemical group [Na+].C1=C[C@H](C)[C@H](CC[C@@H](O)C[C@@H](O)CC([O-])=O)[C@H]2[C@@H](OC(=O)[C@@H](C)CC)C[C@H](O)C=C21 VWBQYTRBTXKKOG-IYNICTALSA-M 0.000 claims description 2
125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 2
229960004604 propranolol hydrochloride Drugs 0.000 claims description 2
AQHHHDLHHXJYJD-UHFFFAOYSA-N propranolol hydrochloride Natural products C1=CC=C2C(OCC(O)CNC(C)C)=CC=CC2=C1 AQHHHDLHHXJYJD-UHFFFAOYSA-N 0.000 claims description 2
229960002855 simvastatin Drugs 0.000 claims description 2
RYMZZMVNJRMUDD-HGQWONQESA-N simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 claims description 2
WUBVEMGCQRSBBT-UHFFFAOYSA-N tert-butyl 4-(trifluoromethylsulfonyloxy)-3,6-dihydro-2h-pyridine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(OS(=O)(=O)C(F)(F)F)=CC1 WUBVEMGCQRSBBT-UHFFFAOYSA-N 0.000 claims description 2
229960002961 ticlopidine hydrochloride Drugs 0.000 claims description 2
MTKNGOHFNXIVOS-UHFFFAOYSA-N ticlopidine hydrochloride Chemical compound [H+].[Cl-].ClC1=CC=CC=C1CN1CC(C=CS2)=C2CC1 MTKNGOHFNXIVOS-UHFFFAOYSA-N 0.000 claims description 2
229960005221 timolol maleate Drugs 0.000 claims description 2
229960004699 valsartan Drugs 0.000 claims description 2
SJSNUMAYCRRIOM-QFIPXVFZSA-N valsartan Chemical compound C1=CC(CN(C(=O)CCCC)[C@@H](C(C)C)C(O)=O)=CC=C1C1=CC=CC=C1C1=NN=N[N]1 SJSNUMAYCRRIOM-QFIPXVFZSA-N 0.000 claims description 2
229960000881 verapamil hydrochloride Drugs 0.000 claims description 2
230000001882 diuretic effect Effects 0.000 claims 4
YRSVDSQRGBYVIY-UHFFFAOYSA-N 2-[2,2-dimethyl-7-oxo-6-[(3-phenyl-2-sulfanylpropanoyl)amino]azepan-1-yl]acetic acid Chemical compound O=C1N(CC(O)=O)C(C)(C)CCCC1NC(=O)C(S)CC1=CC=CC=C1 YRSVDSQRGBYVIY-UHFFFAOYSA-N 0.000 claims 1
101000783577 Dendroaspis angusticeps Thrombostatin Proteins 0.000 claims 1
101000783578 Dendroaspis jamesoni kaimosae Dendroaspin Proteins 0.000 claims 1
QTBSBXVTEAMEQO-UHFFFAOYSA-N acetic acid Substances CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims 1
239000000464 adrenergic agent Substances 0.000 claims 1
239000002160 alpha blocker Substances 0.000 claims 1
229940126317 angiotensin II receptor antagonist Drugs 0.000 claims 1
239000000480 calcium channel blocker Substances 0.000 claims 1
230000007211 cardiovascular event Effects 0.000 claims 1
239000008194 pharmaceutical composition Substances 0.000 claims 1
230000035488 systolic blood pressure Effects 0.000 description 15
239000013543 active substance Substances 0.000 description 13
239000000902 placebo Substances 0.000 description 7
229940068196 placebo Drugs 0.000 description 7
206010020772 Hypertension Diseases 0.000 description 6
230000035487 diastolic blood pressure Effects 0.000 description 6
238000011282 treatment Methods 0.000 description 6
UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 5
208000024172 Cardiovascular disease Diseases 0.000 description 5
102000003729 Neprilysin Human genes 0.000 description 5
108090000028 Neprilysin Proteins 0.000 description 5
102000004270 Peptidyl-Dipeptidase A Human genes 0.000 description 5
108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 5
230000009467 reduction Effects 0.000 description 4
238000004448 titration Methods 0.000 description 4
239000005541 ACE inhibitor Substances 0.000 description 3
238000002648 combination therapy Methods 0.000 description 3
150000001875 compounds Chemical class 0.000 description 3
239000002552 dosage form Substances 0.000 description 3
206010019280 Heart failures Diseases 0.000 description 2
108010007859 Lisinopril Proteins 0.000 description 2
229940044094 angiotensin-converting-enzyme inhibitor Drugs 0.000 description 2
WGQKYBSKWIADBV-UHFFFAOYSA-N benzylamine Chemical compound NCC1=CC=CC=C1 WGQKYBSKWIADBV-UHFFFAOYSA-N 0.000 description 2
230000036772 blood pressure Effects 0.000 description 2
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 2
206010012601 diabetes mellitus Diseases 0.000 description 2
125000005265 dialkylamine group Chemical group 0.000 description 2
230000002526 effect on cardiovascular system Effects 0.000 description 2
238000011156 evaluation Methods 0.000 description 2
238000009472 formulation Methods 0.000 description 2
230000005764 inhibitory process Effects 0.000 description 2
229960002394 lisinopril Drugs 0.000 description 2
RLAWWYSOJDYHDC-BZSNNMDCSA-N lisinopril Chemical compound C([C@H](N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(O)=O)C(O)=O)CC1=CC=CC=C1 RLAWWYSOJDYHDC-BZSNNMDCSA-N 0.000 description 2
238000000034 method Methods 0.000 description 2
239000000126 substance Substances 0.000 description 2
125000005270 trialkylamine group Chemical group 0.000 description 2
BIDNLKIUORFRQP-XYGFDPSESA-N (2s,4s)-4-cyclohexyl-1-[2-[[(1s)-2-methyl-1-propanoyloxypropoxy]-(4-phenylbutyl)phosphoryl]acetyl]pyrrolidine-2-carboxylic acid Chemical compound C([P@@](=O)(O[C@H](OC(=O)CC)C(C)C)CC(=O)N1[C@@H](C[C@H](C1)C1CCCCC1)C(O)=O)CCCC1=CC=CC=C1 BIDNLKIUORFRQP-XYGFDPSESA-N 0.000 description 1
GELMWIVBBPAMIO-UHFFFAOYSA-N 2-methylbutan-2-amine Chemical compound CCC(C)(C)N GELMWIVBBPAMIO-UHFFFAOYSA-N 0.000 description 1
125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
239000004475 Arginine Substances 0.000 description 1
206010003658 Atrial Fibrillation Diseases 0.000 description 1
102000002723 Atrial Natriuretic Factor Human genes 0.000 description 1
101800001288 Atrial natriuretic factor Proteins 0.000 description 1
101800001890 Atrial natriuretic peptide Proteins 0.000 description 1
OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
GHOSNRCGJFBJIB-UHFFFAOYSA-N Candesartan cilexetil Chemical compound C=12N(CC=3C=CC(=CC=3)C=3C(=CC=CC=3)C3=NNN=N3)C(OCC)=NC2=CC=CC=1C(=O)OC(C)OC(=O)OC1CCCCC1 GHOSNRCGJFBJIB-UHFFFAOYSA-N 0.000 description 1
206010007559 Cardiac failure congestive Diseases 0.000 description 1
108010061435 Enalapril Proteins 0.000 description 1
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 1
239000004472 Lysine Substances 0.000 description 1
FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
102000005741 Metalloproteases Human genes 0.000 description 1
108010006035 Metalloproteases Proteins 0.000 description 1
MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 description 1
ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
208000001647 Renal Insufficiency Diseases 0.000 description 1
208000006011 Stroke Diseases 0.000 description 1
230000002159 abnormal effect Effects 0.000 description 1
229910052783 alkali metal Inorganic materials 0.000 description 1
229910052784 alkaline earth metal Inorganic materials 0.000 description 1
150000003973 alkyl amines Chemical class 0.000 description 1
150000001412 amines Chemical class 0.000 description 1
150000001413 amino acids Chemical class 0.000 description 1
ODKSFYDXXFIFQN-UHFFFAOYSA-N arginine Natural products OC(=O)C(N)CCCNC(N)=N ODKSFYDXXFIFQN-UHFFFAOYSA-N 0.000 description 1
230000003143 atherosclerotic effect Effects 0.000 description 1
229960003515 bendroflumethiazide Drugs 0.000 description 1
HDWIHXWEUNVBIY-UHFFFAOYSA-N bendroflumethiazidum Chemical compound C1=C(C(F)(F)F)C(S(=O)(=O)N)=CC(S(N2)(=O)=O)=C1NC2CC1=CC=CC=C1 HDWIHXWEUNVBIY-UHFFFAOYSA-N 0.000 description 1
238000009530 blood pressure measurement Methods 0.000 description 1
229910052791 calcium Inorganic materials 0.000 description 1
239000011575 calcium Substances 0.000 description 1
229960004349 candesartan cilexetil Drugs 0.000 description 1
239000002775 capsule Substances 0.000 description 1
229960000830 captopril Drugs 0.000 description 1
FAKRSMQSSFJEIM-RQJHMYQMSA-N captopril Chemical compound SC[C@@H](C)C(=O)N1CCC[C@H]1C(O)=O FAKRSMQSSFJEIM-RQJHMYQMSA-N 0.000 description 1
239000002327 cardiovascular agent Substances 0.000 description 1
229940125692 cardiovascular agent Drugs 0.000 description 1
NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 1
239000003638 chemical reducing agent Substances 0.000 description 1
235000012000 cholesterol Nutrition 0.000 description 1
238000011260 co-administration Methods 0.000 description 1
239000006071 cream Substances 0.000 description 1
238000013461 design Methods 0.000 description 1
230000003205 diastolic effect Effects 0.000 description 1
239000003085 diluting agent Substances 0.000 description 1
201000010099 disease Diseases 0.000 description 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
230000009977 dual effect Effects 0.000 description 1
230000000694 effects Effects 0.000 description 1
GBXSMTUPTTWBMN-XIRDDKMYSA-N enalapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CCC1)C(O)=O)CC1=CC=CC=C1 GBXSMTUPTTWBMN-XIRDDKMYSA-N 0.000 description 1
229960000873 enalapril Drugs 0.000 description 1
230000029142 excretion Effects 0.000 description 1
238000013265 extended release Methods 0.000 description 1
229960002490 fosinopril Drugs 0.000 description 1
YRSVDSQRGBYVIY-GJZGRUSLSA-N gemopatrilat Chemical compound O=C1N(CC(O)=O)C(C)(C)CCC[C@@H]1NC(=O)[C@@H](S)CC1=CC=CC=C1 YRSVDSQRGBYVIY-GJZGRUSLSA-N 0.000 description 1
229950006480 gemopatrilat Drugs 0.000 description 1
230000001631 hypertensive effect Effects 0.000 description 1
239000012729 immediate-release (IR) formulation Substances 0.000 description 1
238000001802 infusion Methods 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000010255 intramuscular injection Methods 0.000 description 1
239000007927 intramuscular injection Substances 0.000 description 1
208000017169 kidney disease Diseases 0.000 description 1
201000006370 kidney failure Diseases 0.000 description 1
239000000314 lubricant Substances 0.000 description 1
229910052749 magnesium Inorganic materials 0.000 description 1
239000011777 magnesium Substances 0.000 description 1
208000010125 myocardial infarction Diseases 0.000 description 1
208000031225 myocardial ischemia Diseases 0.000 description 1
239000002674 ointment Substances 0.000 description 1
230000002085 persistent effect Effects 0.000 description 1
229910052700 potassium Inorganic materials 0.000 description 1
239000011591 potassium Substances 0.000 description 1
239000003755 preservative agent Substances 0.000 description 1
150000003242 quaternary ammonium salts Chemical class 0.000 description 1
229960001455 quinapril Drugs 0.000 description 1
JSDRRTOADPPCHY-HSQYWUDLSA-N quinapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2=CC=CC=C2C1)C(O)=O)CC1=CC=CC=C1 JSDRRTOADPPCHY-HSQYWUDLSA-N 0.000 description 1
229960003401 ramipril Drugs 0.000 description 1
HDACQVRGBOVJII-JBDAPHQKSA-N ramipril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](C[C@@H]2CCC[C@@H]21)C(O)=O)CC1=CC=CC=C1 HDACQVRGBOVJII-JBDAPHQKSA-N 0.000 description 1
238000009097 single-agent therapy Methods 0.000 description 1
229910052708 sodium Inorganic materials 0.000 description 1
239000011734 sodium Substances 0.000 description 1
229940083542 sodium Drugs 0.000 description 1
229960002909 spirapril Drugs 0.000 description 1
108700035424 spirapril Proteins 0.000 description 1
HRWCVUIFMSZDJS-SZMVWBNQSA-N spirapril Chemical compound C([C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@@H](CC2(C1)SCCS2)C(O)=O)CC1=CC=CC=C1 HRWCVUIFMSZDJS-SZMVWBNQSA-N 0.000 description 1
239000007921 spray Substances 0.000 description 1
239000003381 stabilizer Substances 0.000 description 1
238000007920 subcutaneous administration Methods 0.000 description 1
239000000829 suppository Substances 0.000 description 1
229940066769 systemic antihistamines substituted alkylamines Drugs 0.000 description 1
IMCGHZIGRANKHV-AJNGGQMLSA-N tert-butyl (3s,5s)-2-oxo-5-[(2s,4s)-5-oxo-4-propan-2-yloxolan-2-yl]-3-propan-2-ylpyrrolidine-1-carboxylate Chemical compound O1C(=O)[C@H](C(C)C)C[C@H]1[C@H]1N(C(=O)OC(C)(C)C)C(=O)[C@H](C(C)C)C1 IMCGHZIGRANKHV-AJNGGQMLSA-N 0.000 description 1
YBRBMKDOPFTVDT-UHFFFAOYSA-N tert-butylamine Chemical compound CC(C)(C)N YBRBMKDOPFTVDT-UHFFFAOYSA-N 0.000 description 1
238000011269 treatment regimen Methods 0.000 description 1
230000002485 urinary effect Effects 0.000 description 1
239000003981 vehicle Substances 0.000 description 1
230000002861 ventricular Effects 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
General Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Epidemiology (AREA)
Organic Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Other In-Based Heterocyclic Compounds (AREA)
Nitrogen- Or Sulfur-Containing Heterocyclic Ring Compounds With Rings Of Six Or More Members (AREA)
Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

AU2001287289A 2000-04-03 2001-03-15 Vasopeptidase inhibitors to treat isolated systolic hypertensions Abandoned AU2001287289A1 (en)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US19449900P	2000-04-03	2000-04-03
US60/194499		2000-04-03
PCT/US2001/008240 WO2001074348A2 (fr)	2000-04-03	2001-03-15	Inhibiteurs de vasopeptidase pour traiter l'hypertension systolique isolee

Publications (1)

Publication Number	Publication Date
AU2001287289A1 true AU2001287289A1 (en)	2001-10-15

Family

ID=22717832

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AU2001287289A Abandoned AU2001287289A1 (en)	2000-04-03	2001-03-15	Vasopeptidase inhibitors to treat isolated systolic hypertensions

Country Status (8)

Country	Link
US (1)	US20020004500A1 (fr)
EP (1)	EP1267855A2 (fr)
JP (1)	JP2003533440A (fr)
AU (1)	AU2001287289A1 (fr)
CA (1)	CA2405496A1 (fr)
PE (1)	PE20011316A1 (fr)
UY (1)	UY26648A1 (fr)
WO (1)	WO2001074348A2 (fr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6610716B2 (en) *	2000-07-13	2003-08-26	Alteon Incorporated	Cyanomethyl substituted thiazoliums and imidazoliums and treatments of disorders associated with protein aging
US6777443B2 (en)	2001-05-15	2004-08-17	Novartis Ag	Dipeptide derivatives
WO2003053353A2 (fr) *	2001-12-20	2003-07-03	Bristol-Myers Squibb Company	Reduction de la tension arterielle differentielle et de la rigidite vasculaire chez des patients hypertendus par l'administration d'un inhibiteur de la vasopeptidase
ES2290429T3 (es) *	2002-01-17	2008-02-16	Novartis Ag	Composiciones farmaceuticas que comprenden valsartan e inhibidores de nep.
US7468390B2 (en)	2002-01-17	2008-12-23	Novartis Ag	Methods of treatment and pharmaceutical composition
EP1750862B1 (fr) *	2004-06-04	2011-01-05	Teva Pharmaceutical Industries Ltd.	Composition pharmaceutique contenant de l'irbesartan
WO2007045663A2 (fr) *	2005-10-19	2007-04-26	Novartis Ag	Combinaison de composes organiques
AR057882A1 (es)	2005-11-09	2007-12-26	Novartis Ag	Compuestos de accion doble de bloqueadores del receptor de angiotensina e inhibidores de endopeptidasa neutra
WO2019108653A1 (fr)	2017-11-28	2019-06-06	Anavex Life Sciences Corp.	Traitement de la pression sanguine systolique par un agoniste du récepteur sigma -1

2001
- 2001-03-15 AU AU2001287289A patent/AU2001287289A1/en not_active Abandoned
- 2001-03-15 EP EP01964664A patent/EP1267855A2/fr not_active Withdrawn
- 2001-03-15 JP JP2001572093A patent/JP2003533440A/ja active Pending
- 2001-03-15 CA CA002405496A patent/CA2405496A1/fr not_active Abandoned
- 2001-03-15 WO PCT/US2001/008240 patent/WO2001074348A2/fr not_active Ceased
- 2001-03-28 US US09/819,549 patent/US20020004500A1/en not_active Abandoned
- 2001-04-02 UY UY26648A patent/UY26648A1/es not_active Application Discontinuation
- 2001-04-03 PE PE2001000306A patent/PE20011316A1/es not_active Application Discontinuation

Also Published As

Publication number	Publication date
PE20011316A1 (es)	2002-01-13
WO2001074348A2 (fr)	2001-10-11
CA2405496A1 (fr)	2001-10-11
WO2001074348A8 (fr)	2002-05-23
JP2003533440A (ja)	2003-11-11
UY26648A1 (es)	2001-11-30
EP1267855A2 (fr)	2003-01-02
US20020004500A1 (en)	2002-01-10

Publication	Publication Date	Title
EP1467728B1 (fr)	2007-08-22	Compositions pharmaceutiques a base de valsartan et d'inhibiteurs nep
US8404744B2 (en)	2013-03-26	Methods of treatment and pharmaceutical composition
JP4843172B2 (ja)	2011-12-21	医薬処方物および卒中、糖尿病および／またはうっ血性心不全の予防におけるその使用
WO2007106708A2 (fr)	2007-09-20	Combinaison de composes organiques
US20020004500A1 (en)	2002-01-10	Vasopeptidase Inhibitors to treat isolated systolic hypertension
US20100204190A1 (en)	2010-08-12	New combinations
JP2008524159A (ja)	2008-07-10	ＮＥＰ阻害剤、内因性エンドセリン産生系の阻害剤およびＨＭＧＣｏＡレダクターゼ阻害剤を含有する医薬組成物
JP2002535367A5 (fr)	2007-02-15
US7872035B2 (en)	2011-01-18	Angiotensin II antagonists
US20070142355A1 (en)	2007-06-21	Association of a sinus node If curent inhibitor and an angiotensin converting enzyme inhibitor, and pharmaceutical compositions containing it
Hansson	1999	Recent intervention trials in hypertension initiated in Sweden HOT, CAPPP and others
US20020013307A1 (en)	2002-01-31	Use of vasopeptidase inhibitors to treat or slow the progression of cognitive dysfunction and to treat and/or prevent dementia
US20050267124A1 (en)	2005-12-01	Pharmaceutical compositions comprising NEP-inhibitors, inhibitors of the endogenous producing system and PDEV inhibiitors
EP1753433A1 (fr)	2007-02-21	Compositions pharmaceutiques renfermant des inhibiteurs de l'endopeptidase neutre (nep), des inhibiteurs du systeme de production de l'endotheline endogene et des inhibiteurs de la phosphodiesterase 5 (pde v)
US20030144269A1 (en)	2003-07-31	Reducing pulse pressures and vascular stiffness in hypertensive patients by administering a vasopeptidase inhibitor
HK1106444B (en)	2011-04-21	New association of a sinus node if current inhibitor and an angiotensin-converting enzyme inhibitor, and pharmaceutical compositions containing it
AU2006202999A1 (en)	2006-08-03	Pharmaceutical compositions comprising valsartan and NEP inhibitors
HK1195010A (en)	2014-10-31	Combinations of solifenacin and salivary stimulants for the treatment of overactive bladder